jedijeewa.bsky.social
jedijeewa.bsky.social
jedijeewa.bsky.social
@jedijeewa.bsky.social
Tremendous work by chairs Antonio Cabrera and Shaan Amdani in developing this important scientific statement addressing the challenges of pediatric ADHF!
@americanheart.bsky.social
www.ahajournals.org/doi/10.1161/...
Evaluation and Management of the Child With Acute Decompensated Heart Failure: A Scientific Statement From the American Heart Association | Circulation
Nationally, there has been a rise in the number of children and adolescents with congenital and acquired heart disease presenting with acute decompensated heart failure. Compared with adults, these children have increased morbidity and mortality and use significantly more health care resources once admitted. Currently, there is little guidance on how to assess, manage, and create successful discharge plans for children presenting with acute decompensated heart failure. Given that this population represents an intersection among emergency medicine, cardiology, surgery, critical care, and psychology, a guidance document for the comprehensive management of this high-risk population is needed. This scientific statement reflects the state of current evidence and highlights important knowledge gaps in this domain.
www.ahajournals.org
April 10, 2026 at 1:32 AM
The CCS/CPCA Guideline on Acute Heart Failure in Children is out in the Canadian Journal of Cardiology! An amazing effort by my co-chair Jennifer Conway and an amazing panel of writers
@ccs-scc.bsky.social www.sciencedirect.com/science/arti...
www.sciencedirect.com
April 10, 2026 at 1:27 AM
Reposted by jedijeewa.bsky.social
In the SCOUT-HCM trial, among adolescents with obstructive hypertrophic cardiomyopathy, the cardiac myosin inhibitor mavacamten led to a significantly greater reduction in left ventricular outflow tract obstruction than placebo. Full trial results: nej.md/3Q06X6I

#ACC26 | @accintouch.bsky.social
March 29, 2026 at 3:50 PM
Reposted by jedijeewa.bsky.social
#ACC26 SCOUT-HCM: Mavacamten, a first-in-class drug, was associated with a significant improvement in LVOT gradient compared to placebo in adolescent patients with obstructive hypertrophic cardiomyopathy.

Read the full results ➡️ https://bit.ly/3Q7Vbas #CardioSky
March 29, 2026 at 4:04 PM